Investigational drug · Phase 3
IPN60340
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "IPN60340"
First trial start
2026
Nov 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IPN60340", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukaemia (AML)
- Acute Myeloid Leukaemia
Largest trials
Live from ClinicalTrials.gov: studies naming "IPN60340" as an intervention, largest first.
- A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive ChemotherapyPivotal-lookingNot yet recruiting
IpsenIndustry
NCT07623187 · 540 participants (planned) · Start Nov 1, 2026 · Primary completion May 31, 2031
Drug: IPN60340 + azacitidine + venetoclax; Placebo + azacitidine + venetoclax · For: Acute Myeloid Leukaemia (AML); Acute Myeloid Leukaemia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Acute Myeloid Leukaemia (AML)
- RVU120SEL120Phase 23 trials
Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.